Prevalence and antimicrobial profile of Shigella causing acute diarrheal disease in pediatrics in Posadas, Misiones

Revista de Ciencia y Tecnología Pub Date : 2022-10-31 DOI:10.36995/j.recyt.2022.38.009

S. Grenón, L. Leguizamón, A. del Valle, S. Pallarès, M. S. Salvi Grabulosa, M. V. von Specht

{"title":"Prevalence and antimicrobial profile of Shigella causing acute diarrheal disease in pediatrics in Posadas, Misiones","authors":"S. Grenón, L. Leguizamón, A. del Valle, S. Pallarès, M. S. Salvi Grabulosa, M. V. von Specht","doi":"10.36995/j.recyt.2022.38.009","DOIUrl":null,"url":null,"abstract":"Our objective was to evaluate the presence and microbiological characteristics of Shigella in children with acute diarrhoeal disease (ADD), attended at the Paediatric Hospital of Posadas, Misiones between 2016 and 2019. All ADEs documented in the laboratory were included. Standardised microbiological techniques were used. We considered age groups: infants (L)≤ 2 years, preschool (PE): 3-5 years, school (E): 5- 14 years. We recorded 106/2128 (5%) Shigella spp. isolates, with a higher frequency in summer (54.5%). S. flexneri (64; 60.4% serotypes 02(54), 03(3), AA479(2) and 01(1)) and S. sonnei (37; 34.9%) predominated. Mean age: 4.2 years (1.2 m-11a). Those < 5 years old were the most affected (70 %). Hospitalisation was required in 7.7%. S. flexneri/S. sonnei were: in L (42.9% vs 27.7%) and in E (27 vs 42.9%). Overall resistance to AMP was 72.7% and 58.1% to TMS. 97% were sensitive to furazolidone (FUR), cefpodoxime and fluorinated quinolones. In S. flexneri the % resistance to AMP/TMS was (78.7/44.8) and in S. sonnei (61.8/80.6) p< 0.05). We detected 6 resistance phenotypes with low multi-resistance (2.6%). FUR remains an empirical therapeutic option in outpatients.","PeriodicalId":21243,"journal":{"name":"Revista de Ciencia y Tecnología","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Ciencia y Tecnología","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36995/j.recyt.2022.38.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Our objective was to evaluate the presence and microbiological characteristics of Shigella in children with acute diarrhoeal disease (ADD), attended at the Paediatric Hospital of Posadas, Misiones between 2016 and 2019. All ADEs documented in the laboratory were included. Standardised microbiological techniques were used. We considered age groups: infants (L)≤ 2 years, preschool (PE): 3-5 years, school (E): 5- 14 years. We recorded 106/2128 (5%) Shigella spp. isolates, with a higher frequency in summer (54.5%). S. flexneri (64; 60.4% serotypes 02(54), 03(3), AA479(2) and 01(1)) and S. sonnei (37; 34.9%) predominated. Mean age: 4.2 years (1.2 m-11a). Those < 5 years old were the most affected (70 %). Hospitalisation was required in 7.7%. S. flexneri/S. sonnei were: in L (42.9% vs 27.7%) and in E (27 vs 42.9%). Overall resistance to AMP was 72.7% and 58.1% to TMS. 97% were sensitive to furazolidone (FUR), cefpodoxime and fluorinated quinolones. In S. flexneri the % resistance to AMP/TMS was (78.7/44.8) and in S. sonnei (61.8/80.6) p< 0.05). We detected 6 resistance phenotypes with low multi-resistance (2.6%). FUR remains an empirical therapeutic option in outpatients.

查看原文本刊更多论文

在波萨达斯，米西奥尼的儿科引起急性腹泻病的志贺氏菌的流行和抗菌谱

我们的目标是评估2016年至2019年在米西奥内斯波萨达斯儿科医院就诊的急性腹泻病(ADD)儿童中志贺氏菌的存在和微生物学特征。所有在实验室记录的ade都包括在内。采用标准化微生物学技术。我们考虑了年龄组:婴儿(L)≤2岁，学龄前儿童(PE): 3-5岁，学校(E): 5- 14岁。志贺氏菌分离株106/2128株(5%)，夏季发生率较高(54.5%)。flexneri (64;60.4%血清型02(54)、03(3)、AA479(2)、01(1)和sonnei沙门氏菌(37);34.9%)成为主流。平均年龄:4.2岁(1.2 m-11a)。5岁以下儿童受影响最大(70%)。需要住院治疗的占7.7%。美国flexneri / S。分别为:L组(42.9% vs 27.7%)和E组(27% vs 42.9%)。对AMP和TMS的总体耐药率分别为72.7%和58.1%。97%对呋喃唑酮、头孢多肟和氟喹诺酮类药物敏感。flexneri和sonnei对AMP/TMS的耐药率分别为(78.7/44.8)和(61.8/80.6)，p< 0.05。我们检测到6种低多重耐药表型(2.6%)。FUR仍然是门诊患者的经验性治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista de Ciencia y Tecnología

自引率

0.00%

发文量